id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-269975-1ebmq7t8	Duplantier, Allen J.	Combating biothreat pathogens: ongoing efforts for countermeasure development and unique challenges	2020-05-27		.txt	text/plain	12963	580	32	None of the filoviruses or henipaviruses has any FDA-approved therapeutics or vaccines available for prevention or treatment of human disease, and while ribavirin is sometimes used to treat Lassa fever, it is not a terribly effective drug against this viral infection [28] . Many of the therapeutics that are in different stages of either preclinical or clinical development for select biothreat pathogens include small molecule antivirals (Tables 7.3 and 7.4), antibody (or antibody cocktails) against viruses or bacteria/virulence factors (Table 7 .5), and combination drug therapy (Table 7 .6). Although no FDA-approved HDT therapies are yet available for treating infectious diseases, we have summarized in this section the antimicrobial Primary screening of small molecule chemical libraries in the phenotypic HCI assay will identify compounds that inhibit pathogen infection as well as those that may contribute to cellular toxicity.	./cache/cord-269975-1ebmq7t8.txt	./txt/cord-269975-1ebmq7t8.txt